Press Room

4th APV Continuous Manufacturing Conference

Start
Tuesday, May 09, 2023 - 09:00
End
Thursday, May 11, 2023 - 17:00
Location: Lisbon, Portugal
Hovione Lumiar Buildings R and S - aerial view

Hovione will be present and sponsor (gold sponsors) the 4th APV Continuous Manufacturing Conference from May 9-11. Don’t miss the chance to meet with our experts and learn more about the future of continuous manufacturing and how continuous tableting is right for your product. Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.

 

HOVIONE PRESENTATIONS

Tuesday, 09 May 2023 | Session 1: Manufacturing experience

A Roadmap to establish continuous tableting as a mainstream industrial platform
José Luís Santos - R&D Director - CoE Continuous Tableting

Tuesday, 09 May 2023 | Session 2: Process control

Control strategies for robust continuous manufacturing of oral dosage forms
Anthony Tantuccio - Fellow Scientist, Corporate Continuous Man. Project

Wednesday, 10 May 2023 | Session 4: Novel CM approaches

Enabling direct compression of amorphous solid dispersions
João Henriques - R&D Senior Manager, Formulation Development

 

The conference will be held in Lisbon - Portugal and includes a visit to our two sites: Hovione Lumiar and Hovione Loures.

 

Learn more about Continuous Tableting at Hovione

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025